CVRx (CVRX) – Analysts’ Recent Ratings Changes

CVRx (NASDAQ: CVRX) has recently received a number of price target changes and ratings updates:

• 8/17/2026 – CVRx had its price target lowered by Cantor Fitzgerald from $13.00 to $5.00. They now have an “overweight” rating on the stock.
• 8/8/2026 – CVRx was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/7/2026 – CVRx was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $4.00 price target on the stock.
• 8/7/2026 – CVRx was downgraded by Craig Hallum from “buy” to “hold”. They now have a $4.00 price target on the stock.
• 8/7/2026 – CVRx was downgraded by Lake Street Capital from “buy” to “hold”. They now have a $3.50 price target on the stock, down from $14.00.
• 8/3/2026 – CVRx had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In related news, COO Brent Binkowski purchased 26,223 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were purchased at an average price of $2.91 per share, with a total value of $76,308.93. Following the acquisition, the chief operating officer directly owned 56,514 shares of the company’s stock, valued at approximately $164,455.74. This represents a 86.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 16.60% of the stock is currently owned by corporate insiders.

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.